Monoclonal antibody · Immune activation, directed at programmed cell death 1 ligand 1 (CD274) · developed by CytomX Therapeutics
Pacmilimab is a recombinant antibody prodrug whose anti-PD-L1 antibody is masked by a peptide linked through a protease-cleavable linker. Tumor-associated proteases cleave the mask, allowing the active antibody to bind PD-L1 and block its interaction with PD-1 on T-cells. It is studied in solid tumors and unresectable or metastatic melanoma, including in combination with ipilimumab.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03993379 | Phase 2 | Solid Tumor | Terminated | CTMX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid TumorUnresectable or Metastatic Melanoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the CTMX page.
See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CTMX catalysts and pipeline →